You just read:

Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

News provided by

Shire plc

May 18, 2017, 07:00 ET